Revision of PRECAUTIONS
Posaconazole

May 8, 2024

**Therapeutic category**
Antibiotic preparations acting mainly on mold

**Non-proprietary name**
Posaconazole

**Safety measure**
PRECAUTIONS should be revised.
2. CONTRAINDICATIONS (This drug is contraindicated to the following patients.)

Patients receiving the following drugs: Ergotamine tartrate/anhydrous caffeine/isopropylantipyrine, dihydroergotamine, methylergometrine, ergometrine, simvastatin, atorvastatin, pimozide, quinidine, venetoclax [during its dose escalation phase for relapsed or refractory chronic lymphocytic leukemia (including small lymphocytic lymphoma)], suvorexant, lurasidone hydrochloride, blonanserin, triazolam

10. INTERACTIONS
10.1 Contraindications for Co-administration (Do not co-administer with the following.)
(N/A)

<table>
<thead>
<tr>
<th>Drugs</th>
<th>Signs, symptoms, and treatment</th>
<th>Mechanism/risk factors</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rivaroxaban</td>
<td>The anticoagulant effect of rivaroxaban may be enhanced, and a risk of haemorrhage may be increased.</td>
<td>The plasma concentration of rivaroxaban is expected to rise due to the inhibition of CYP3A4, as well as the possible inhibition of P-gp, by co-administration with posaconazole.</td>
</tr>
</tbody>
</table>

N/A: Not Applicable. No corresponding language is included in the current PRECAUTIONS.